How to Apply to Dr. Reddy's Laboratories

11 min read Last updated April 20, 2026 1 open positions
Blake Crosley
Blake Crosley Researched using publicly available information, hiring data, and ATS analysis.

Key Takeaways

  • Dr. Reddy's is one of India's largest and most globally significant pharmaceutical companies, with deep US generics, biosimilars, API/CDMO, and Russia/CIS commercial businesses.
  • The company is family-influenced (Reddy family promoters, G.V. Prasad as Co-Chairman, Satish Reddy as Chairman) but professionally led globally by CEO Erez Israeli since 2019.
  • Hiring is heaviest in Hyderabad (R&D, regulatory, quality, manufacturing) with significant US presence in Princeton and Bridgewater, New Jersey, and a Latin America hub in Cuernavaca, Mexico.
  • Applications run through SmartRecruiters at careers.drreddys.com — keyword-precise, parser-friendly resumes win the recruiter scan.
  • Interviews are technically deep and fact-based; have specific molecules, filings, inspections, or accounts ready to walk through end-to-end.
  • Compensation is competitive within each local market: ₹15–60 LPA for mid-to-senior India roles, $130–260K base for mid-to-senior US roles, with strong benefits everywhere.
  • Strategic priorities to align with: complex generics, biosimilars, consumer health (post-Haleon NRT acquisition), and US/India regulatory excellence.
  • Long-term mobility across India, US, Mexico, and Russia is real — flagging openness to relocation can materially improve your candidacy for senior roles.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Ltd. (NYSE: RDY, BSE: 500124, NSE: DRREDDY) is one of India's largest and most globally relevant pharmaceutical companies, headquartered in Hyderabad, Telangana. Founded in 1984 by the late Dr. Anji Reddy — a chemist widely credited as the father of the modern Indian generic export industry — the company has grown into a multinational employing roughly 26,000 people across India, the United States, Europe, Russia/CIS, Latin America, the United Kingdom, and emerging markets. Annual revenue for FY2024 was approximately ₹290 billion (about $3.5 billion USD), with the United States generics business as its single largest revenue contributor and growing strategic emphasis on biosimilars, complex generics (injectables, ophthalmics, inhalation, nasal), and consumer/OTC health. The company operates three primary businesses. Global Generics is the largest segment and includes high-volume ANDA-driven US generics (where Dr. Reddy's competes with Teva, Sandoz, Hikma, Sun Pharma, Aurobindo, Lupin, and Cipla), India branded prescription, Russia/CIS — where Dr. Reddy's holds a top-tier position in retail pharmacy — and Europe, Brazil, and emerging markets. The Pharmaceutical Services & Active Ingredients (PSAI) segment manufactures active pharmaceutical ingredients (APIs) for both internal formulation use and external CDMO customers, and has gained geopolitical relevance as the United States and Europe seek to diversify API sourcing away from China. Proprietary Products & Biosimilars commercializes differentiated branded specialty products and a growing biosimilars portfolio — notably, Reditux (rituximab biosimilar), launched in 2007, was the first cancer biosimilar developed and commercialized from an emerging-market company. Leadership combines professional global pharma operators with founding-family stewardship. Erez Israeli, an Israeli executive who joined from Teva, has served as Chief Executive Officer since 2019 and has been credited with sharpening operational discipline and accelerating the biosimilars and complex-generics roadmap. G.V. Prasad, son of founder Dr. Anji Reddy, serves as Co-Chairman and remains deeply involved in long-term strategy; his brother Satish Reddy serves as Chairman. The Reddy family retains a controlling promoter stake. Recent strategic moves include the 2024 acquisition of Haleon's nicotine replacement therapy (NRT) portfolio outside the United States for approximately $633 million — a significant step into consumer health and OTC. The company continues to invest heavily in biosimilars (monoclonal antibodies, fusion proteins), complex injectables, peptides, and digital/AI-enabled R&D, with roughly 2,000+ R&D scientists across multiple Hyderabad and Bangalore centers. Major manufacturing and R&D sites include Hyderabad (HQ plus Bachupally, Bollaram, Miyapur, Jeedimetla), formulations plants in Goa and Visakhapatnam, US commercial headquarters in Princeton and Bridgewater, New Jersey, a key Latin America hub in Cuernavaca, Mexico, sites in Russia, Malaysia, Brazil, and the former BMS Mirfield plant in the United Kingdom.

Application Process

  1. 1
    Apply through careers

    Apply through careers.drreddys.com — the official SmartRecruiters-powered careers portal — rather than third-party aggregators, so your application enters the canonical applicant tracking system.

  2. 2
    Create a complete SmartRecruiters profile with parsed work history, education, a

    Create a complete SmartRecruiters profile with parsed work history, education, and skills; recruiters frequently filter saved searches on these structured fields rather than free-text resume content.

  3. 3
    Tailor your resume to the specific requisition: mirror the exact terminology use

    Tailor your resume to the specific requisition: mirror the exact terminology used in the job description (for example, 'ANDA filings,' 'DMF,' 'bioequivalence,' 'Form 483 remediation,' 'biosimilar CMC,' 'Russia commercial').

  4. 4
    Expect an initial recruiter screen within one to three weeks for India roles and

    Expect an initial recruiter screen within one to three weeks for India roles and two to four weeks for US/Mexico roles; high-volume India requisitions can receive hundreds to thousands of applicants.

  5. 5
    Complete one to two technical or functional interviews

    Complete one to two technical or functional interviews — for R&D, regulatory, and quality roles these will probe specific molecules, dossiers, inspections, or therapeutic areas you have worked on.

  6. 6
    Prepare for a final-round panel or skip-level discussion with a Vice President o

    Prepare for a final-round panel or skip-level discussion with a Vice President or Senior Director, especially for senior individual contributor and people-leader roles.

  7. 7
    Anticipate detailed reference and background verification, including education v

    Anticipate detailed reference and background verification, including education verification through agencies such as First Advantage or AuthBridge in India — Indian regulators take pharma credentialing seriously.

  8. 8
    Negotiate compensation transparently: India offers are typically structured as f

    Negotiate compensation transparently: India offers are typically structured as fixed CTC plus variable performance bonus plus long-term incentive for senior bands; US offers include base, target bonus, and RSUs/stock-linked plans.

  9. 9
    Total timeline runs four to eight weeks from first application to verbal offer f

    Total timeline runs four to eight weeks from first application to verbal offer for most roles; specialized US regulatory and senior R&D leadership roles can extend to ten to twelve weeks.

  10. 10
    Onboarding is structured: India sites have multi-week orientation with site safe

    Onboarding is structured: India sites have multi-week orientation with site safety, GxP, and code-of-conduct modules; US Princeton/Bridgewater onboarding emphasizes US compliance, anti-bribery, and ICH-GCP refreshers.

Resume Tips for Dr. Reddy's Laboratories

recommended

Lead with regulatory and quality milestones using exact language: 'Filed 12 ANDA

Lead with regulatory and quality milestones using exact language: 'Filed 12 ANDAs with USFDA,' 'Authored 3 DMF Type II submissions,' 'Led Form 483 response and CAPA closure for sterile injectable site.'

recommended

Quantify product impact: number of molecules, market share gained, cost-out deli

Quantify product impact: number of molecules, market share gained, cost-out delivered in API, scale-up volumes, or biosimilar dossier milestones such as Phase 3 enrollment or 351(k) submission.

recommended

Name specific dossier types and pathways relevant to Dr

Name specific dossier types and pathways relevant to Dr. Reddy's pipeline: ANDA, 505(b)(2), MAA, biosimilar 351(k), Health Canada, ANVISA, EMA decentralized procedure, CDSCO India.

recommended

Surface peer-company experience explicitly — Sun Pharma, Cipla, Lupin, Aurobindo

Surface peer-company experience explicitly — Sun Pharma, Cipla, Lupin, Aurobindo, Glenmark, Torrent, Cadila/Zydus, Biocon, Teva, Sandoz, Mylan/Viatris, Hikma — recruiters actively scan for this.

recommended

For US roles, highlight US generics commercial knowledge: 340B, Medicare Part D,

For US roles, highlight US generics commercial knowledge: 340B, Medicare Part D, PBM dynamics (Express Scripts, CVS Caremark, OptumRx), GPO contracting, and channel inventory management.

recommended

For R&D roles, list specific dosage forms (oral solids, sterile injectables, oph

For R&D roles, list specific dosage forms (oral solids, sterile injectables, ophthalmics, inhalation, nasal, depot), analytical techniques (HPLC, LC-MS, dissolution, characterization of biologics), and CMC experience.

recommended

Cite degrees from recognized Indian pharma institutions — NIPER (any campus), Ma

Cite degrees from recognized Indian pharma institutions — NIPER (any campus), Manipal, ICT Mumbai, BITS Pilani, Jadavpur — alongside any US/EU degrees; Indian recruiters strongly recognize these credentials.

recommended

List languages thoughtfully: Hindi and Telugu are practical assets for Hyderabad

List languages thoughtfully: Hindi and Telugu are practical assets for Hyderabad operations; Russian is highly valued for CIS commercial roles; Spanish and Portuguese matter for the Cuernavaca and Brazil businesses.

recommended

Keep formatting simple: single-column, standard fonts (Arial, Calibri, Times New

Keep formatting simple: single-column, standard fonts (Arial, Calibri, Times New Roman), no tables or graphics — SmartRecruiters parses cleanly but breaks on complex layouts.

recommended

Save and submit as PDF generated from Word; include a hyperlinked LinkedIn profi

Save and submit as PDF generated from Word; include a hyperlinked LinkedIn profile that mirrors your resume exactly, since recruiters cross-check before any internal slate review.

ATS System: SmartRecruiters

Dr. Reddy's runs its global careers portal at careers.drreddys.com on SmartRecruiters, a widely used enterprise applicant tracking and recruitment marketing platform. Applications are parsed into structured fields, and recruiters and hiring managers screen using saved searches against those fields rather than resume free text alone. SmartRecruiters supports requisition-level workflows, recruiter and hiring manager scorecards, structured interview guides, and offer management — meaning every stage you complete is logged and visible to the talent acquisition team across geographies.

  • Match your resume keywords to the precise terminology in the job posting — SmartRecruiters surfaces candidates to recruiters in part by keyword density and structured field matches.
  • Fully populate the structured profile fields (job titles, employer names, dates, education, certifications) rather than relying on resume parsing alone; saved searches often filter on these fields.
  • Upload a single, clean PDF resume; avoid embedded images, headers/footers with contact info, and multi-column layouts that can confuse the parser.
  • List relevant certifications explicitly: USFDA cGMP, ICH-GCP, Lean Six Sigma, PMP, RAC (Regulatory Affairs Certification), or ASQ Certified Quality Engineer where applicable.
  • Use industry-standard section headings (Experience, Education, Skills, Certifications, Publications, Patents) so the parser maps content correctly into SmartRecruiters fields.
  • Apply only to roles you genuinely fit — SmartRecruiters tracks application history per candidate, and high-volume low-quality applications can dampen recruiter response.
  • If you applied previously and were declined, wait at least six months and apply only when you have materially new credentials or a clearly different role match.

Interview Culture

Interviews at Dr.

Reddy's are structured, technically rigorous, and respectful in tone — reflecting both the regulated nature of pharma and the company's Indian engineering/scientific heritage that prizes substantive depth over interview theatrics. Expect pointed, fact-based questions about your actual molecules, dossiers, inspections, validation studies, market launches, or commercial accounts; vague answers are a signal of weak fit. R&D and regulatory candidates should be ready to walk through specific filings end-to-end: rationale for the 505(b)(2) pathway chosen, CMC strategy, bioequivalence design and pivotal study results, FDA queries received, and how they were resolved. Quality and manufacturing candidates should expect deep dives into specific Form 483 observations, Warning Letter remediations, deviation investigations, CAPA closure, and process validation lifecycles per ICH Q8/Q9/Q10/Q11. Commercial candidates in the US should be prepared to discuss customer-specific dynamics with the major distributors and PBMs, generic launch sequencing, and pricing pressure under the Inflation Reduction Act; commercial candidates in India should expect questions on multi-tier distribution, MR (medical representative) effectiveness, and brand strategy. Cultural fit is assessed through scenario questions on cross-site collaboration (Hyderabad ↔ Princeton ↔ Cuernavaca time zones are real), comfort working with founding-family-influenced governance alongside professional global leadership, and resilience under regulatory pressure. Interviews are professional and courteous — Indian pharma is a relatively small community and reputations travel — so be candid about prior employers and outcomes; embellishment is easily verified through reference checks and is a fast disqualifier.

What Dr. Reddy's Laboratories Looks For

  • Demonstrated regulatory craft — ANDA, DMF, MAA, or 351(k) experience with named programs you can defend in detail rather than résumé-padded keywords.
  • Form 483 and Warning Letter remediation literacy — comfort with cGMP investigations, root cause analysis, CAPA, and inspection readiness culture.
  • Therapeutic and dosage-form depth in priority Dr. Reddy's spaces: complex injectables, ophthalmics, inhalation, nasal, peptides, biosimilar mAbs, and oncology supportive care.
  • Indian or global big-pharma scale experience — the company operates at industrial volumes, and small-batch-only backgrounds usually need bridging context.
  • Commercial fluency for the relevant geography — US generics channel, Russia/CIS retail pharmacy, India multi-tier branded prescription, or Latin America institutional and retail.
  • Cross-cultural collaboration skills — comfort working across Hyderabad, Princeton, Cuernavaca, and Russia time zones with mixed Indian, American, Mexican, and European colleagues.
  • Strong written communication in English — regulatory dossiers, deviation reports, and internal escalations are all written artifacts that withstand audit.
  • Ethical track record — pharma is heavily regulated under the FCPA in the US, the UK Bribery Act, and India's evolving compliance regime; clean records and willingness to escalate are non-negotiable.
  • Ownership and execution rigor — Dr. Reddy's culture rewards people who close issues to root cause rather than escalate prematurely.
  • Long-arc career thinking — the company invests meaningfully in internal mobility (India ↔ US ↔ Mexico ↔ Russia) and prefers candidates open to multi-year geographic moves.

Frequently Asked Questions

How does compensation compare between Hyderabad, Princeton, and Cuernavaca?
Each location pays competitively within its local market rather than on a single global band. In Hyderabad, mid-level scientists and managers typically land in the ₹15–30 LPA range, senior managers and associate directors in the ₹35–60 LPA range, and senior leadership from ₹80 LPA into multi-crore territory inclusive of variable and long-term incentives. In Princeton and Bridgewater, New Jersey, mid-level roles are generally $130,000–180,000 base with target bonus, while director-and-above roles run $180,000–260,000+ base with meaningful equity-linked incentives, in line with the broader US generics industry. Cuernavaca, Mexico compensation is competitive with leading multinational pharma in Mexico and includes strong statutory and supplementary benefits. All three locations include robust benefits — provident fund, gratuity, and group medical in India; comprehensive 401(k), medical, dental, vision, and life in the US; and IMSS plus supplementary private medical in Mexico.
Is Dr. Reddy's still operating in Russia, and what does that mean for commercial careers there?
Yes. Dr. Reddy's has been one of the leading pharmaceutical companies in the Russian retail pharmacy market for many years and has continued to operate there following 2022, focused on essential medicines. The Russia/CIS commercial organization remains a real career path, particularly for candidates with Russian language ability and prior experience in the CIS pharma market. Candidates evaluating these roles should make their own informed assessment of the geopolitical and sanctions context; the company has publicly emphasized its focus on continuing to supply essential medicines and operating within applicable laws.
How does a career at Dr. Reddy's compare to Sun Pharma, Cipla, Lupin, or Aurobindo?
All of these are major Indian pharma employers and there is meaningful talent flow between them. Sun Pharma is the largest by market cap and has a particularly strong specialty/branded US business. Cipla has historically been very strong in India branded prescription and respiratory. Lupin has deep US generics experience. Aurobindo has scale in API and US generics with a heavy injectables push. Dr. Reddy's distinguishing strengths are its US generics scale combined with a serious biosimilars program, a strong API/CDMO franchise, the Russia/CIS commercial footprint, and the Hyderabad R&D center concentration. Compensation bands across these companies are broadly comparable; differentiation usually comes down to specific therapeutic area, dosage-form expertise, and reporting line rather than total cash.
Where should an R&D scientist focus — US generics, biosimilars, or complex generics?
All three are growth areas at Dr. Reddy's, but they call for different skills. Classical US generics ANDA work remains the volume engine and is deeply institutionalized — it is a strong base for Indian R&D careers. Complex generics (sterile injectables, ophthalmics, inhalation, nasal, peptides, depot formulations) are where the company is investing for differentiation and pricing power, and where careers are accelerating fastest right now. Biosimilars (mAbs, fusion proteins) are a long-arc strategic bet with a smaller but rapidly growing team and a learning curve that can open doors to global biologics roles. If you are early-career and choosing, complex generics and biosimilars typically offer faster skill compounding.
How important is direct USFDA inspection or Form 483 remediation experience?
Very important for quality, manufacturing, regulatory, and senior R&D roles. Like all major Indian pharma companies, Dr. Reddy's has worked through its share of FDA observations over the years, and the company values colleagues who can speak credibly about inspection readiness, deviation investigations, CAPA closure, data integrity, and cross-functional remediation programs. If you have led or contributed to a successful 483 response or Warning Letter remediation, surface that prominently — it materially raises your priority in the recruiter screen.
Does Dr. Reddy's sponsor work visas in the US, and are India-to-US transfers possible?
Yes, for specialized roles. The Princeton and Bridgewater commercial, regulatory, and R&D teams sponsor H-1B and L-1 visas for hard-to-fill specialist positions, and intra-company transfers from India to the US do happen — particularly in regulatory affairs and US-facing R&D leadership. Sponsorship is more selective at junior and mid-levels and more available at senior individual contributor and people-manager bands. Be candid about visa status during the recruiter screen; the talent acquisition team will route you to roles where sponsorship is realistic.
What kinds of roles are based in Princeton and Bridgewater, New Jersey?
The US footprint is primarily commercial, regulatory, and senior R&D leadership. Roles include US generics commercial (national accounts, marketing, pricing), regulatory affairs (ANDAs, 505(b)(2), labeling, post-marketing), medical affairs, pharmacovigilance, supply chain and trade, finance, legal/compliance, and IT/digital functions supporting the US business. Site-based manufacturing roles in the US are limited; most production happens at Indian and Mexican sites.
Are there formal intern or new-graduate programs?
Yes, especially in India. Dr. Reddy's actively recruits from NIPER campuses, ICT Mumbai, Manipal, BITS Pilani, IITs (for chemical engineering and biotechnology), and leading pharmacy schools nationwide for early-career R&D, manufacturing, and quality roles. There are also structured programs for finance, business analytics, and supply chain. In the US, the company runs a more limited internship pipeline focused on regulatory affairs, commercial analytics, and pharmacovigilance, often tied to PharmD candidates and graduate students at Northeast US programs.
How does the leadership balance work between the Reddy family and CEO Erez Israeli?
The Reddy family — Co-Chairman G.V. Prasad and Chairman Satish Reddy — sets long-term strategic direction and stewards the company's mission and culture as founding-family promoters. CEO Erez Israeli, who joined as CEO in 2019 from Teva, runs day-to-day operations and has been credited with sharpening operational discipline and accelerating the biosimilars and complex-generics roadmap. In practice, employees experience a professional global pharma operating model with founding-family stewardship in the background — closer to Roche's Hoffmann influence model than to a tightly family-run company. Strategic decisions of consequence are typically aligned across both.
How seriously should I take FDA inspection history when evaluating an offer?
Take it seriously, but in context. Every major Indian pharma manufacturer — including Dr. Reddy's, Sun Pharma, Cipla, Lupin, and Aurobindo — has had FDA observations and remediation cycles over the years; this is the structural reality of regulated manufacturing at scale. What matters is the specific site you would be joining, its current inspection status, the maturity of its quality systems, and the leadership team's track record on remediation. Ask in interviews about the site's most recent inspection outcome, current EIR status, and the quality investments planned over the next two years. Strong candidates ask these questions and recruiters expect them.
How is biosimilars career growth at Dr. Reddy's compared to Biocon or Samsung Bioepis?
Biocon (and Biocon Biologics) is the largest dedicated biosimilars employer in India and the natural reference point. Samsung Bioepis (in partnership with Organon and historically Merck) is the major Korean biosimilars player. Dr. Reddy's biosimilars team is smaller than Biocon's but growing, and offers strong experience for scientists who want exposure to both biosimilars and a broader generics/complex-generics organization on the same campus. If you want to specialize purely in biologics for the long term, Biocon and Samsung Bioepis are deeper. If you want biosimilars exposure within a diversified pharma career, Dr. Reddy's is a strong choice.
What is the company's stance on remote and hybrid work?
Like most regulated pharma manufacturers, on-site presence is the default for R&D, manufacturing, quality, and analytical roles — these jobs require physical lab and plant access. Commercial, regulatory, medical affairs, IT, finance, and corporate functions in both India and the US typically operate hybrid (commonly three days on-site), with policies set at the function and site level. Fully remote roles are rare and usually limited to specialized regulatory or medical specialist positions. Confirm specifics during the recruiter screen rather than assuming.

Open Positions

Dr. Reddy's Laboratories currently has 1 open positions.

Check Your Resume Before Applying → View 1 open positions at Dr. Reddy's Laboratories

Related Resources

Similar Companies

Related Articles

Sources

  1. Dr. Reddy's Laboratories — Official Careers Portal —
  2. Dr. Reddy's Laboratories — About Us —
  3. Dr. Reddy's Laboratories — Investor Relations —
  4. Dr. Reddy's Laboratories Ltd. — SEC Form 20-F (Annual Report, Foreign Private Issuer) —
  5. NSE India — DRREDDY Equity Information —
  6. BSE India — Dr. Reddy's Laboratories (500124) —
  7. Dr. Reddy's to Acquire Haleon's Global (ex-US) Nicotine Replacement Therapy Portfolio — Company Press Release (2024) —
  8. Erez Israeli — CEO, Dr. Reddy's Laboratories (LinkedIn / Company Bio) —
  9. Dr. Anji Reddy, Founder of Dr. Reddy's Laboratories, Dies at 72 — The New York Times (2013) —
  10. Anji Reddy: The Man Who Built India's Generic Drug Industry — Economic Times (2013) —
  11. U.S. Food and Drug Administration — Inspections Database —
  12. SmartRecruiters — Applicant Tracking & Recruitment Marketing Platform —
  13. Dr. Reddy's Laboratories — Glassdoor Company Profile (Hyderabad) —
  14. Dr. Reddy's Laboratories — LinkedIn Company Page —
  15. India Pharma Industry Outlook — EY India Reports —